Skip to contentApplication 761136
- Type
- BLA
- Sponsor
- CELGENE CORP
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | REBLOZYL | LUSPATERCEPT-AAMT | POWDER;SUBCUTANEOUS | 25MG/VIAL | No | No |
| 002 | REBLOZYL | LUSPATERCEPT-AAMT | POWDER;SUBCUTANEOUS | 75MG/VIAL | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-711 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-711 | Luspatercept | Luspatercept | Celgene | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Reblozyl | Luspatercept | Celgene Corporation | BLA | Current |
| 59572-775 | Luspatercept | Luspatercept | Celgene | BLA | Current |